{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:03:40Z","timestamp":1791201820303,"version":"4.2.0"},"reference-count":9,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T00:00:00Z","timestamp":1204588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In order to evaluate the previously published association between maternal use of selective serotonin re\u2010uptake inhibitors (SSRI) and persistent pulmonary hypertension in the neonate (PPHN), we used data from the Swedish Medical Birth Register for the years 1997\u20132005. Infants were identified from discharge diagnoses, and maternal exposure to drugs from interviews performed in early pregnancy and from prescriptions from the antenatal care service. Putative confounders were studied: an increased risk for PPHN was indicated for high maternal age, for first parity, for maternal BMI, and possibly for maternal smoking. Adjusting for these variables and year of birth, an association between maternal use of SSRI and PPHN in births after 34 completed weeks was identified with a risk ratio of 2.4, 95%CI 1.2\u20134.3 when based on women who reported the drug use in early pregnancy. When a subgroup of the women were studied who also had prescriptions for SSRI from the antenatal care later in pregnancy, the risk estimate was 3.6, 95%CI 1.2\u20138.3. The risk estimates were lower than that described previously in the literature, but both estimates could come from the same about 4\u20135 times increased risk. The mechanism behind the association between SSRI and PPHN is unclear but an increased risk for respiratory problems after maternal use of SSRI is well known, and PPHN could be a rare part of this association. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/pds.1570","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T11:46:46Z","timestamp":1204631206000},"page":"801-806","source":"Crossref","is-referenced-by-count":170,"title":["Maternal use of selective serotonin re\u2010uptake inhibitors and persistent pulmonary hypertension of the newborn"],"prefix":"10.1002","volume":"17","author":[{"given":"Bengt","family":"K\u00e4ll\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra Otterblad","family":"Olausson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2006.04.211"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052744"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351402"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.97.5.658"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2307\/3433243"},{"key":"e_1_2_1_7_2","unstructured":"National Board of Health and Welfare.Centre for Epidemiology The Swedish Medical Birth Register\u2014a Summary of Content and Quality. Available at:http:\/\/www.sos.se\/FULLTEXT\/112\/2003\u2010112\u20103\/2003\u2010112\u20103.pdf[Accessed on 10 October 2007]."},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/JRS-2001-263","article-title":"Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias?","volume":"14","author":"K\u00e4ll\u00e9n B","year":"2001","journal-title":"Int J Risk Saf Med"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.4.357"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0258-0"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1570","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T22:14:34Z","timestamp":1738102474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,4]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1002\/pds.1570"],"URL":"https:\/\/doi.org\/10.1002\/pds.1570","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,4]]}}}